PATIENTS | Locally-advanced And Metastatic Pancreatic Cancer
Locally-advanced And Metastatic Pancreatic Cancer
Pancreatic cancer that has spread
Clinical Trial Results
- Phase IIB/IIIA clinical trial studying Theracim use in combination with Gemcitabine in patients with locally advanced or metastatic pancreatic cancer showed longer survival of 8.6 months compared to patients that received Gemcitabine alone with 6.0 months.
*Your doctor may recommend treatment with Theracim based on the stage of your cancer, or your overall health. Please consult with your doctor for more information.
What is Pancreatic cancer?
Pancreatic cancer, specifically pancreatic ductal adenocarcinoma is a type of cancer that arises in the duct of gland in pancreas, which lies behind the stomach and in front of the spine19. Locally advanced pancreatic cancer is a type of pancreatic cancer which has spread from the site of the original tumor only to surrounding tissue or lymph nodes and cannot be removed completely through surgery. Metastatic pancreatic cancer is a type of pancreatic cancer that has spread to the distant sites or organs in the body.
How many people have Pancreatic cancer?
Pancreatic cancer is slightly rare with 338,000 of new cases in 2012. It was estimated that 85-90% of pancreatic cancer patients were presented with locally advanced or metastatic disease.
What are the risks for getting Pancreatic cancer?
It is important to know that having 1 or more risk factors does not mean that you will certainly have pancreatic cancer and some people may get this type of cancer even if they don’t have any risk factors. The risk factors that are associated with pancreatic cancer:
- Family histoy
- Chronic pancreatitis
- Diabetes mellitus
- H. pylori infection
- Non-O-blood group
- Red meat intake